Ansell Limited (ASX:ANN): FY26 Earnings, Safety Products and FY27 Outlook

Aditi Sarkar

23 October 2026 04:27 PM AEDT

Ansell Limited (ASX:ANN): FY26 Earnings, Safety Products and FY27 Outlook

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Ansell (ASX:ANN) reported FY26 sales of US$2.14 billion, an increase of 6.8%.
Statutory net profit reached US$208.6 million, compared with US$101.6 million in FY25.
Operating cash flow increased to US$270.1 million, while adjusted EBIT reached US$321.9 million.
FY27 adjusted EPS guidance is US158–170 cents; the company opened a new surgical glove plant in India.

Ansell Limited manufactures and supplies protective gloves, clothing and other personal safety products for healthcare and industrial workplaces across more than 100 countries. On 23 October 2026, Ansell (ASX:ANN) was quoted at AUD 45.97, up 0.46% for the trading session. The company’s recent updates cover its FY26 financial results, manufacturing productivity, the opening of its India surgical glove facility and expectations for FY27.

Company Business

Ansell (ASX:ANN) operates two reporting segments, Healthcare and Industrial. Healthcare encompasses surgical gloves, examination and single-use protection, and cleanroom products for hospitals, laboratories, pharmaceutical production and controlled manufacturing environments. The Industrial division supplies mechanical and chemical protection products to workplaces requiring resistance to cuts, chemicals and other occupational hazards.

Its brands include GAMMEX, MICROFLEX, TouchNTuff, HyFlex, AlphaTec and Ringers. Demand differs across the two segments: healthcare purchases depend on clinical activity and specialised protection requirements, while industrial orders reflect manufacturing activity, end-market investment and customers’ inventory policies. Ansell combines international manufacturing and sourcing with distribution to hospitals, industrial users and specialist customers.

Recent Development

In August 2026, Ansell (ASX:ANN) released its FY26 results and detailed measures addressing US import tariffs and additional costs linked to the Middle East crisis. The company reported that sourcing changes and selling-price increases offset those cost pressures in FY26. It also indicated that further pricing adjustments could be considered if tariff rates or supply-chain costs change.

The group stated that its Accelerated Productivity Investment Program had achieved its US$50 million recurring pre-tax savings target. Attention has shifted to information-technology upgrades, with enterprise resource planning implementation scheduled to begin in North America in FY27. Anticipated total one-off cash costs for the broader program remain US$85–90 million.

In September, Ansell inaugurated a surgical glove manufacturing facility in Kovai, India. The company said production for its domestic market had commenced, with additional capacity planned to serve overseas markets. The facility adds another manufacturing location to a supply network serving healthcare customers in multiple regions.

Financial Performance and Sector Context

For the year ended 30 June 2026, Ansell (ASX:ANN) recorded sales of US$2,140.2 million, compared with US$2,003.3 million in FY25, representing reported growth of 6.8%. Organic constant-currency sales rose 5.0%. Adjusted EBIT increased 14.1% to US$321.9 million, from US$282.1 million; the adjusted EBIT margin rose to 15.0% from 14.1%.

Statutory net profit after tax was US$208.6 million, against US$101.6 million a year earlier. Adjusted net profit rose to US$212.3 million from US$183.3 million, while adjusted earnings per share increased to US148.6 cents from US126.1 cents. Adjusted measures exclude significant items and therefore differ from the statutory results.

Healthcare segment sales reached US$1,192.9 million and adjusted EBIT was US$170.7 million. Industrial segment sales were US$947.3 million, with adjusted EBIT of US$170.6 million. Ansell noted increased demand for synthetic surgical gloves and cleanroom products, alongside improved industrial sales in selected North American markets.

Operating cash flow rose to US$270.1 million from US$105.4 million in FY25. The company reported net debt to adjusted EBITDA of 1.3 times at 30 June 2026 and US$752 million in cash and undrawn bank facilities. The full-year dividend was US68.1 cents per share, compared with US50.2 cents in FY25. Buybacks completed during FY26 totalled US$118.4 million.

Risks to Consider

Ansell (ASX:ANN) remains exposed to changes in hospital purchasing patterns, industrial demand, international tariffs, freight availability and raw-material costs. Price adjustments may not coincide with cost increases, creating timing effects on margins. Currency movements and hedging results influence reported earnings. The staged expansion of manufacturing operations and ERP upgrades also involves delivery, spending and operational-transition risks.

What to Watch Next

For FY27, Ansell (ASX:ANN) forecast adjusted EPS of US158–170 cents, compared with US148.6 cents in FY26. Its planning assumptions include capital expenditure of US$45–55 million, approximately US$43 million in net interest expense and about US$15 million in one-off pre-tax costs, mainly associated with ERP implementation. These figures are guidance rather than realised results.

The company also plans to continue its US$200 million on-market buyback program and will hold its annual general meeting on 9 November 2026. Future reporting will provide further evidence of volume trends, pricing effectiveness, operational efficiencies and the pace of capacity expansion in India.

Key Insights

Ansell’s FY26 results recorded growth in revenue, earnings and operating cash flow across a business serving healthcare and industrial customers. For Ansell (ASX:ANN), subsequent developments to monitor include delivery against FY27 earnings guidance, manufacturing investment, cost recovery through pricing and progress in operational simplification.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.